Witness the Eli Lilly & Co. Zepbound injection pen showcased in the vibrant Brooklyn borough of New York, USA, captured on Thursday, March 28, 2024.
Photographed by the talented Shelby Knowles for Bloomberg | Getty Images.
In a groundbreaking move, the Food and Drug Administration granted approval on Friday for Eli Lilly’s revolutionary weight loss medication Zepbound to be used in treating individuals suffering from the prevalent sleep-related breathing disorder. This decision not only broadens its application but also opens up possibilities for potential insurance coverage across America.
This weekly injectable solution now stands as a pioneering treatment option specifically designed for patients grappling with obesity and moderate-to-severe obstructive sleep apnea (OSA), a condition characterized by disrupted breathing patterns during sleep due to constricted or blocked air passages. The FDA emphasized that Zepbound should be complemented with a calorie-controlled diet and increased physical activity to maximize its effectiveness.
An alarming statistic reveals that an estimated 80 million Americans are affected by this ailment according to Eli Lilly’s data. Shockingly, around 20 million individuals suffer from moderate-to-severe OSA; however, a staggering 85% of cases remain undiagnosed as disclosed by the company…
2024-12-20 17:47:31
Read more at www.cnbc.com